MBX Biosciences (MBX) Net Cash Flow (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Net Cash Flow data on file, last reported at -$29.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 53.59% year-over-year to -$29.9 million; the trailing twelve-month figure through Mar 2026 stood at $15.5 million (up 380.99% YoY), and the FY2025 full-year result was $25.9 million, up 37.76% from the prior year.
• Net Cash Flow improved to -$29.9 million in Q1 2026, from -$147.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $183.3 million in Q3 2025 to a low of -$147.8 million in Q4 2025.
• A 4-year average of -$2.5 million and a median of -$21.2 million in 2024 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 143.09% in 2025, while the deepest fall reached 496.74% in 2025.
• Tracing MBX's Net Cash Flow over 4 years: stood at -$40.1 million in 2023, then slumped by 108.36% to -$83.5 million in 2024, then plunged by 77.02% to -$147.8 million in 2025, then jumped by 79.8% to -$29.9 million in 2026.
• Business Quant data shows MBX's Net Cash Flow at -$29.9 million in Q1 2026, -$147.8 million in Q4 2025, and $183.3 million in Q3 2025.